

Table S3: Patient characteristics PRADO

| Characteristics | Total cohort (n=49) | |
|------------------------------|---------------------|--------|
| Institute | | |
| Netherlands Cancer Institute | 49 | (100%) |
| Age, years (median, IQR) | 58, 52-68 | |
| Sex | | |
| Men | 32 | (65%) |
| Women | 17 | (35%) |
| Primary tumor stage | | |
| T1a/b | 6 | (12%) |
| T2a/b | 13 | (27%) |
| T3a/b | 13 | (27%) |
| T4a/b | 12 | (24%) |
| Tx | 1 | (2%) |
| Unknown primary | 4 | (8%) |
| Pathologic response | | |
| Yes | 38 | (78%) |
| No | 11 | (22%) |
| Recurrence ^a | | |
| Yes | 12 | (24%) |
| No | 37 | (76%) |
| Alive ^a | | |
| Yes | 45 | (92%) |
| No | 4 | (8%) |

^a At data cutoff (7 February 2022), the median follow-up from data of registration was 28.1 months, with a minimum follow-up of 23.4 months for all patients alive.
IQR; interquartile range